From: Statin prescription among patients with type 2 diabetes in Botswana: findings and implications
Characteristics | All (N = 477) | Males (n = 160) | Females (n = 317) |
---|---|---|---|
Age, mean(SD), years | 60.3(10.8) | 56.8(11.5) | 62.0(10.1) |
Age > 40 years n(%) | 461(96.7) | 150(93.8) | 311(98.1) |
Diabetes duration, median, IQR, years | 7(3–13) | 8.9(3–14) | 7 (3–13) |
Diabetes duration > 10 years n(%) | 164 (34.4) | 63(39.4) | 101(31.9) |
BMI, mean (SD) kg/m2 | 30.7(6.0) | 29.0(5.2) | 31.6(6.1) |
 Normal weight n(%) | 85(17.8) | 39(24.4) | 46(14.5) |
 Overweight n(%) | 146(30.6) | 59(36.7) | 87(27.4) |
 Obese n(%) | 246(51.6) | 62(38.8) | 184(58.0) |
Marital status | |||
 Living alone n(%) | 247(51.8) | 47(29.4) | 200(63.1) |
 Living with a partner n(%) | 230(48.2) | 113(70.6) | 117(36.9) |
Education status | |||
  ≤ Primary education, n(%) | 306(64.1) | 82(51.3) | 224(70.7) |
  ≥ Secondary or tertiary, n(%) | 171(35.9) | 78(48.7) | 93(29.3) |
WHR, mean (SD) | 0.94(0.10) | 0.97(0.08) | 0.93(0.09) |
 Low WHR n (%) | 79(16.6) | 67(41.9) | 12(3.8) |
 High WHR n (%) | 398(83.4) | 93(58.1) | 305(96.2) |
Hypertension n (%) | 404(84.7) | 120(75.0) | 284(89.6) |
Use of antihypertensive n (%) | 389(81.6) | 110(68.8) | 279(88.0) |
Smoking n (%) | 16(3.4) | 12(7.5) | 4(1.3) |
Lipid-lowering medications n (%) | 224(47.0) | 70(43.8) | 154(48.6) |
 Statins n (%) | 217(45.5) | 68(42.5) | 149(47.0) |
 Others n (%) | 7(1.5) | 2(1.6) | 5(1.6) |
CVD n (%) | 42(8.8) | 15(9.4) | 27(8.5) |
 PAD n (%) | 11(2.3) | 3(1.9) | 8(2.5) |
 Coronary artery disease n (%) | 12(2.5) | 5(3.3) | 7(2.2) |
 Cerebrovascular disease n (%) | 22(4.6) | 8(5.0) | 14(4.4) |
CKD n (%) | 54(11.3) | 24(15.0) | 30(9.5) |
Proteinuria n (%) | 51(10.7) | 27(16.9) | 24(7.6) |
HbA1c mean (SD), % | 8.4(2.4) | 8.5(2.6) | 8.3(2.3) |
Baseline LDL-C, mean (SD), mmol/L | 3.1(1.2) | 2.8(1.1) | 3.3(1.2) |
 Normal | 315(66.0) | 113(70.6) | 202(63.7) |
 High | 59(12.4) | 9(5.6) | 50(15.8) |
 Missing | 103(21.6) | 38(23.8) | 65(20.5) |